In this review, we comprehensively explore the anti-tumor and protumor aspects of the cGAS-STING pathway, discuss the challenges in its clinical application, and propose potential strategies for optimizing its clinical utility, paving the way for more effective and personalized cancer immunotherapies. The gene discussed is CGAS; the disease is neoplasm.